COVID-19

Evusheld concentrations remained elevated in serum for 6 months after administration, supporting that a single dose could provide long-term protection against COVID-19.

Almost all the participants who had not had COVID-19 seroconverted after vaccination, meaning they made antibodies against the virus.

Of the 53 pediatric patients enrolled in the CARAVAN study, no new safety signals were apparent for patients treated with remdesivir.

The PREVENT-19 study evaluates the immunogenicity and safety of a third dose of NVX-CoV2373 in children aged 12 to 17 years.

COVID-19 is associated with longer stays in the intensive care unit, which costs nearly twice as much to treat.

ARCT-154 demonstrates 95% efficacy overall for prevention of severe disease, including related deaths.

Depression can make people who have recovered from COVID-19 feel less enthusiastic in their daily lifestyle.

The booster vaccine candidate includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants such as the Omicron variant.

The CIC is a combination of Novavax’s COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.

Each time a pharmacist immunizes a patient against one of the 27 infections for which a safe and effective vaccine exists, the profession continues to protect communities against diseases that wreaked havoc on generations.

Evusheld has been found to significantly reduce the risk of developing symptomatic COVID-19.

Heart-related complications in children with COVID-19 are uncommon, but case reports have noted cardiogenic shock, myocarditis, pericarditis, and arrhythmias.

The companies plan to submit these data to the FDA in the coming days for an Emergency Use Authorization of a booster dose for children ages 5 through 11 in the United States.

Individuals with immunity obtained through having the disease still experienced expanded T-cell memory and immune activation after being immunized, study results show.

Obesity and a limited physical activity are key factors in post-COVID-19 recovery.

Study captures the immune effect of the third dose of the COVID-19 vaccine in patients with plasma cell disorders and blood cancers.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

The value of a patient-first approach and telehealth for addressing the complex health care coordination needs of patients with rare pulmonary diseases has never been more critical than during the COVID-19 pandemic.

Investigators followed men and women aged 20 to 40 years without pre-existing disease, and findings indicate that obesity and physical inactivity increase the impact of the disease.

How would you handle these patients' questions?

Despite their lower antibody responses, patients who are vaccinated receive protection from SARS-CoV-2 infection and severe disease.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Investigators also identified that a polymerase inhibitor with a unique modification largely resists its removal from the RNA by the exonuclease.